Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.

Navid DashtiForough Golsaz-ShiraziHaleh SoltanghoraeeAmir-Hassan ZarnaniMehdi MohammadiDanyal ImaniMahmood Jeddi-TehraniMohammad Mehdi AmiriShokri Fazel

Published in: European journal of microbiology & immunology (2024)

RBD-Fc elicits highly robust neutralizing antibodies and cellular immune responses, with no adverse effects. Therefore, it could be considered a promising and safe subunit vaccine against SARS-CoV-2.

Keyphrases

sars cov
immune response
respiratory syndrome coronavirus
cell therapy
dengue virus
stem cells
cell free
bone marrow
mesenchymal stem cells
clinical evaluation